Limbic and HPA axis function in an animal model of chronic neuropathic pain

被引:109
作者
Ulrich-Lai, Yvonne M.
Xie, Wenrui
Meij, Johanna T. A.
Dolgas, C. Mark
Yu, Lei
Herman, James P.
机构
[1] Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45140 USA
[2] Univ Cincinnati, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45140 USA
关键词
chronic stress; CCI; corticosterone; glucocorticoid receptor; corticotropin releasing hormone;
D O I
10.1016/j.physbeh.2006.03.012
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Chronic pain can be considered a form of chronic stress, and chronic pain patients often have disturbances of the hypothalamic-pituitaryadrenal (HPA) axis, including abnormal cortisol levels. In addition, chronic pain patients have an increased incidence of depression and anxiety, stress-related disorders that are frequently accompanied by disturbances in the limbic system (e.g. hippocampus and amygdala) and the HPA axis. Despite the fact that the literature supports a strong link between chronic pain, stress disorders, and limbic dysfunction, the mechanisms underlying the effects of chronic pain on the HPA axis and limbic system are not understood. The current study employs a rodent neuropathic pain model (chronic constriction injury (CCI) of the sciatic nerve) to assess the long-term impact of chronic pain on the HPA axis and limbic system. Adult male rats received CCI or sham surgery; nociceptive behavioral testing confirmed CCI-induced neuropathic pain. Tests of HPA axis function at 13-23 days postsurgery demonstrated teat CCI did not affect indices of basal or restraint stress-induced HPA axis activity. CCI increased the expression of corticotrophin releasing hormone mRNA in the central amygdala, and not the paraventricular nucleus of the hypothalamus or the bed nucleus of the stria terminalis. Moreover, glucocorticoid receptor mRNA expression in CCI rats was increased in the medial and central amygdala, unaffected in the paraventricular nucleus, and decreased in the hippocampus. These results suggest that increased nociceptive sensitivity during chronic pain is associated with alterations in the limbic system, but is dissociated from HPA axis activation. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 79 条
[31]   Hypothalamic-pituitary-adrenal response to chronic stress in five inbred rat strains: Differential responses are mainly located at the adrenocortical level [J].
Gomez, F ;
Lahmame, A ;
deKloet, ER ;
Armario, A .
NEUROENDOCRINOLOGY, 1996, 63 (04) :327-337
[32]  
Griep EN, 1998, J RHEUMATOL, V25, P1374
[33]   A NEW AND SENSITIVE METHOD FOR MEASURING THERMAL NOCICEPTION IN CUTANEOUS HYPERALGESIA [J].
HARGREAVES, K ;
DUBNER, R ;
BROWN, F ;
FLORES, C ;
JORIS, J .
PAIN, 1988, 32 (01) :77-88
[34]   Abuse-related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain [J].
Heim, C ;
Ehlert, U ;
Hanker, JP ;
Hellhammer, DH .
PSYCHOSOMATIC MEDICINE, 1998, 60 (03) :309-318
[35]   REGULATORY CHANGES IN NEUROENDOCRINE STRESS INTEGRATIVE CIRCUITRY PRODUCED BY A VARIABLE STRESS PARADIGM [J].
HERMAN, JP ;
ADAMS, D ;
PREWITT, C .
NEUROENDOCRINOLOGY, 1995, 61 (02) :180-190
[36]   Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis [J].
Herman, JP ;
Prewitt, CMF ;
Cullinan, WE .
CRITICAL REVIEWS IN NEUROBIOLOGY, 1996, 10 (3-4) :371-394
[37]   LOCALIZATION AND REGULATION OF GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR MESSENGER-RNAS IN THE HIPPOCAMPAL-FORMATION OF THE RAT [J].
HERMAN, JP ;
PATEL, PD ;
AKIL, H ;
WATSON, SJ .
MOLECULAR ENDOCRINOLOGY, 1989, 3 (11) :1886-1894
[38]   Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness [J].
Herman, JP ;
Figueiredo, H ;
Mueller, NK ;
Ulrich-Lai, Y ;
Ostrander, MM ;
Choi, DC ;
Cullinan, WE .
FRONTIERS IN NEUROENDOCRINOLOGY, 2003, 24 (03) :151-180
[39]   The corticosteroid receptor hypothesis of depression [J].
Holsboer, F .
NEUROPSYCHOPHARMACOLOGY, 2000, 23 (05) :477-501
[40]  
Iredale PA, 1996, MOL PHARMACOL, V50, P1103